• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

June 23, 2025 By Sean Whooley

Biolinq intradermal glucose sensor
The investigational intradermal glucose sensor. [Image courtesy of Biolinq]
A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy.

Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago.

Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino acid. Released from skeletal muscle breakdown and exogenous protein ingestion, it serves as a key marker, according to a news release. The study evaluated the biosensor’s ability to track lean muscle mass (LLMM) and protein ingestion in patients taking GLP-1s. GLP-1s offer treatment for diabetes and obesity but can lead to the loss of muscle mass.

The system — similar to continuous glucose monitoring (CGM) uses a new method of continuously sensing specific chemistry changes on tiny dermal microsensors. Biolinq’s method uses single-stranded DNA segments (the aptamers) created to specifically identify products of protein breakdown.

Biolinq also develops its sensor technology for the purpose of monitoring glucose. It aims to offer the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device.

The company describes its initial product as “a wearable biosensor powered by an array of tiny electrochemical sensors that measure glucose levels continuously just beneath the skin’s surface.” It closed a $100 million Series C funding round to support the technology earlier this year.

More about the study results shared by Biolinq

Results demonstrated the effective detection of phenylalanine to continuously monitor protein levels. Findings indicate the stability of the sensor over time, linear performance and minimal sensitivity loss over seven days.

The company says the minimal reduction in sensitivity and limit of detection suggests that the basic principles of operation are confirmed. With improved attachment and blocking, the company believes the sensor could work for a longer period with stronger performance.

Biolinq plans for the next phase of its research to focus on conducting clinical trials to evaluate performance in real-world settings.

“GLP-1 medications have transformed the treatment of diabetes and obesity, but they can also increase the risk of muscle loss,” said Rebecca Gottlieb, VP of Advanced Sensor Technologies at Biolinq and lead author of the study. “While patients are advised to consume more protein to preserve muscle, it’s often difficult to know if they’re getting enough. That is why solutions to bridge this gap by providing real-time feedback are more important than ever — especially for those on GLP-1 therapies, older adults, or anyone managing sarcopenia.”

Filed Under: Clinical Trials, Diabetes, Featured, Implants, Patient Monitoring, Technology Tagged With: ADA 2025, biolinq

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS